

Standalone Information		For the Quarter ended on		For the year ended on
		30.6.2011	30.6.2010	31st March 11
Sr. No.	PARTICULARS	(UNAUDITED)	(UNAUDITED)	(AUDITED)
	Revenue	3,301.77	4,205.91	15,712.40
	Profit Before Tax from Ordinary activities	(30.09)	120.99	(13,272.61)
	Profit After Tax from Ordinary activities	(30.09)	120.99	(13,757.24)
	Profit After Tax after extraordinary item	(30.09)	120.99	(21,778.92)

Notes:


- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.08.2011
- 2 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 3 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 4 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 5 As reported earlier, the outstanding of principal value of Foreign Currency Convertible Bonds(The Bond) of USD 43,999,000, which have become due for redemption with redemption premium of USD 19,887,548, has not been redeemed.
- 6 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 7 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 8 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.

Date: 12.08.2011

Visit us at www.marksanspharma.com

For MARKSANS PHARMA LIMITED


MARK SALDANHA
 Managing Director.

